Benzinga | Mar 1, 2021 11:10AM EST

JP Morgan Initiates Coverage On Landos Biopharma with Neutral Rating, Announces Price Target of $17

JP Morgan analyst Jessica Fye initiates coverage on Landos Biopharma (NASDAQ:LABP) with a Neutral rating and announces Price Target of $17.